John S. McBride
Independent DirectorMr. John S. McBride, MS, MBA, was Chief Financial Officer at Luc Therapeutics, Inc. (also known as Cadent Therapeutics) since August 21, 2019 until March 2021. He has an experience of executive leadership, business development and financial experience in the biopharmaceutical industry, serving as Chief Financial Officer of Syntimmune through its acquisition by Alexion Pharmaceuticals, Inc. and a wealth of experience in corporate finance coupled with deep expertise in biopharmaceutical operations and strategy. Mr. McBride is founder and serves as Co-President, Chief Strategy Officer and Senior Partner at Translation Consulting & Brand Imaging, LLC. He served as the Chief Financial Officer at Syntimmune, Inc. Mr. McBride had been Chief Financial Officer and Principal Accounting Officer of Tokai Pharmaceuticals, Inc. since September 1, 2016 to May 2017. He had been the Chief Operating Officer of Tokai Pharmaceuticals, Inc. since February 11, 2014 to May 2017. He served as an Interim Chief Financial Officer of Tokai Pharmaceuticals, Inc. from April 11, 2014 to September 2014. Mr. McBride founded and served as president of Alliance Life Science Advisors, Inc. from March 2012 until February 2014. He served as the Chief Operating Officer and Executive Vice President of Gloucester Pharmaceuticals Inc. since November 2004. He spent many years with Eastman Kodak Company honing his experiences in product design, innovation practice and new business development. He served as Global Head of Oncology Licensing of Pharmacia Corporation where he was involved in numerous in-licensing and out-licensing projects. Previously, he served as an Executive Vice President of Business Operations and Chief Financial Officer of Hydrotherapeutics, Inc. He served as Executive Vice President of business operations and chief financial officer of CytoTherapeutics, Inc. Mr. McBride served as an Independent Consultant from January 2009 to March 2012. Mr. McBride served as Vice President of Business Development and Treasurer of Phytera, Inc., Vice President of Commercial Development at Sparta Pharmaceuticals, Inc. Vice President of Business Development at US Bioscience, Inc. and served various positions with Eastman Kodak and Atlantic Richfield Company. He is involved in development and marketing of several anti-cancer drugs including Camptosar, Ellence, Emcyt, Ethyol, Hexalen, Istodax, Sutent and Vidaza. He serves as Independent Director at Eledon Pharmaceuticals, Inc. (formerly known as Novus Therapeutics, Inc.) since May 2017. He has been a Director of Intezyne Technologies, Inc., since June 2013. He served as a Director of Niiki Pharma Inc. Mr. McBride holds a B.S in Biochemistry and an M.S. in Chemical Engineering from University of Wisconsin and an MBA from Wharton School, University of Pennsylvania.
公司職務
- 公司名稱Eledon Pharmaceuticals, Inc.股票代碼ELDN職務Independent Director共事同僚
- DCDavid-Alexandre C. GrosCEO & Non Independent Director
- KAKeith A. KatkinIndependent Chairman of the Board
- SNSteven N. PerrinPresident, Chief Scientific Officer & Non Independent Director
- PSPaul Sean LittleChief Financial Officer
- JHJohn HerbergerVice President of Technical Operations
- BEBryan E. SmithGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- JAJames A. RobinsonIndependent Director
